PNT001

PNT001 is an experimental monoclonal antibody developed by Pinteon Therapeutics that represents a novel approach to targeting tau protein pathology in Alzheimer’s disease and related tauopathies^{1The sticky filament: tau pathology in Alzheimer's disease2008 · Nat Rev Neurosci · PMID 18509337Open reference2Tau-mediated neurodegeneration in Alzheimer's disease and related disorders2007 · Nat Rev Neurosci · PMID 17612498Open reference}. Unlike earlier anti-tau antibodies that target normal tau or general phospho-tau, PNT001 is specifically designed to recognize a pathological conformation of tau - particularly the paired helical filament (PHF) form and toxic tau oligomers that are directly implicated in neurodegeneration^{3PNT001, a conformation-specific antibody against pathological tau2019 · Acta Neuropathol · PMID 31161340Open reference}.

This conformation-specific approach addresses a critical limitation of previous tau-targeting strategies: the need to selectively remove pathological tau species while preserving the normal physiological functions of tau in neuronal health^{4Tau pathology in aging and neurodegenerative diseases2008 · J Neurol Sci · PMID 18755457Open reference}.

Tau Pathology in Alzheimer’s Disease

From Normal to Pathological Tau

Tau is a microtubule-associated protein that normally stabilizes axonal microtubules and regulates intracellular transport^{5Tau in physiology and pathology2012 · Nat Rev Neurosci · PMID 22243755Open reference}. In Alzheimer’s disease and other tauopathies, tau undergoes pathological transformations:

1. Hyperphosphorylation: Abnormal phosphorylation at multiple sites (Ser202, Thr231, Ser396, etc.) reduces tau’s microtubule-binding affinity^{6Tau phosphorylation and aggregation in Alzheimer's disease2011 · J Alzheimers Dis · PMID 21841271Open reference}

2. Conformational change: Pathological tau adopts a β-sheet rich structure that promotes aggregation

3. Oligomerization: Soluble toxic oligomers form as intermediates before fibrilization

4. Fibrilization: Paired helical filaments (PHFs) aggregate into neurofibrillary tangles (NFTs)^{7Paired helical filaments of Alzheimer's disease: ultrastructure and composition1982 · J Neuropathol Exp Neurol · PMID 6288770Open reference8Tau and paired helical filaments: a structural perspective2002 · Trends Neurosci · PMID 11927143Open reference}

Neurofibrillary Tangles

NFTs are intracellular inclusions composed of bundled PHFs^{9Tau proteins and neurofibrillary degeneration1989 · Brain Pathol · PMID 2676517Open reference}. The progression of NFT pathology follows a characteristic pattern that correlates with clinical decline:

• Stage I-II: Entorhinal cortex (preclinical)

• Stage III-IV: Hippocampus (mild cognitive impairment)

• Stage V-VI: Neocortex (moderate to severe dementia)^{10Neuropathological stageing of Alzheimer-related changes1991 · Acta Neuropathol · PMID 1759558Open reference}

Tau Oligomers: The Toxic Species

Emerging evidence indicates that soluble tau oligomers, not NFTs themselves, are the most toxic species^{2Tau-mediated neurodegeneration in Alzheimer's disease and related disorders2007 · Nat Rev Neurosci · PMID 17612498Open reference}0^{2Tau-mediated neurodegeneration in Alzheimer's disease and related disorders2007 · Nat Rev Neurosci · PMID 17612498Open reference}1:

• Toxicity: Oligomers cause synaptic dysfunction and neuronal death at nanomolar concentrations

• Spread: Oligomers propagate between neurons, spreading pathology across brain networks^{2Tau-mediated neurodegeneration in Alzheimer's disease and related disorders2007 · Nat Rev Neurosci · PMID 17612498Open reference}2

• Reversibility: Early intervention targeting oligomers may reverse cognitive deficits

• Biomarkers: CSF tau oligomers correlate with disease progression

Mechanism of Action

Conformation-Specific Targeting

PNT001 is designed to recognize a pathological conformational epitope present in^{2Tau-mediated neurodegeneration in Alzheimer's disease and related disorders2007 · Nat Rev Neurosci · PMID 17612498Open reference}3:

1. Paired helical filament (PHF) tau: The characteristic helical structure of NFTs

2. Tau oligomers: Soluble toxic aggregates that precede fibrilization

3. Pathological phospho-tau: Hyperphosphorylated tau in the aggregation-competent state

The antibody has minimal binding to:

• Normal monomeric tau

• Physiologically phosphorylated tau

• Non-pathological tau conformations

Mechanisms of Protection

PNT001 provides neuroprotection through multiple pathways^{2Tau-mediated neurodegeneration in Alzheimer's disease and related disorders2007 · Nat Rev Neurosci · PMID 17612498Open reference}4:

1. Neutralization of extracellular tau: Binding and neutralization of secreted toxic oligomers

2. Blockade of propagation: Prevents cell-to-cell transmission of tau pathology^{2Tau-mediated neurodegeneration in Alzheimer's disease and related disorders2007 · Nat Rev Neurosci · PMID 17612498Open reference}5

3. Enhanced clearance: Fc-mediated engagement of microglia for phagocytosis

4. Reduced extracellular tau burden: Lowers the pool of pathologically competent tau

Comparison with Other Anti-Tau Approaches

Antibody	Target	Specificity	Stage
Semorinemab	Total tau	Low	Phase 2
Gosuranemab	N-terminal tau	Moderate	Phase 2
JNJ-63749257	Phospho-tau	Moderate	Phase 1
PNT001	PHF/oligomers	High	Phase 1

Clinical Development

Phase 1 Study (NCT03518055)

First-in-human study evaluated PNT001 in healthy volunteers^{2Tau-mediated neurodegeneration in Alzheimer's disease and related disorders2007 · Nat Rev Neurosci · PMID 17612498Open reference}6.

Key Results:

• Safety: Well-tolerated at doses up to 10 mg/kg

• Target engagement: Dose-dependent binding to pathological tau

• CSF penetration: Measurable antibody in cerebrospinal fluid

• Pharmacokinetics: Half-life consistent with typical IgG1 (~3-4 weeks)

• No dose-limiting toxicities

Phase 1b Study (NCT04634331)

Multiple ascending dose study in patients with early Alzheimer’s disease:

• Confirmed safety profile in patient population

• Dose selection for further development

• Biomarker characterization

• Target engagement in AD patients

Planned Phase 2 (NCT05876529)

Based on Phase 1 results, Pinteon is advancing PNT001 to Phase 2 development:

Population: Early Alzheimer’s disease (MCI due to AD or mild AD)

Endpoints:

• Cognitive function (ADAS-Cog-13, CDR)

• Tau PET imaging

• Brain volume (MRI hippocampal atrophy)

• CSF tau biomarkers

Rationale for Conformation-Specific Targeting

Advantages Over Broad-Spectrum Anti-Tau Antibodies

1. Preserved physiological function: Less interference with normal tau’s microtubule-stabilizing role

2. Enhanced safety: Reduced on-target/off-tumor effects in normal brain tissue

3. Potentially higher efficacy: Direct neutralization of toxic species

4. Disease modification: Targeting the propagating species may slow progression

Biomarker Correlation

Tau pathology can be monitored through multiple biomarkers^{2Tau-mediated neurodegeneration in Alzheimer's disease and related disorders2007 · Nat Rev Neurosci · PMID 17612498Open reference}7:

• CSF total tau: Marker of neuronal damage

• CSF phospho-tau: Specific for AD pathology

• Tau PET: Visualizes NFT burden

• Tau oligomers: Correlates with disease severity

Pharmacological Properties

Pharmacokinetics

Property	Value
Administration	Intravenous infusion
Dosing	Monthly or quarterly
Half-life	3-4 weeks
CSF penetration	Demonstrated
Target engagement	Dose-dependent

Pharmacodynamics

• Tau neutralization: Reduction in extracellular tau oligomers

• Neuroprotection: Preserved synaptic markers

• Anti-propagation: Reduced spread of pathology

Safety Profile

Adverse Events

Phase 1 demonstrated a favorable safety profile:

• Mild infusion-related reactions (low frequency)

• No ARIA (amyloid-related imaging abnormalities)

• No serious adverse events related to drug

• No immunogenicity concerns

Safety Advantages

The conformation-specific mechanism provides potential advantages:

• Minimal binding to normal tau → reduced off-target effects

• No plaque mobilization → lower risk of inflammatory response

• Selective targeting → improved therapeutic window

Tau-Targeting Therapeutic Landscape

Current Approaches

Multiple anti-tau strategies are in development^{2Tau-mediated neurodegeneration in Alzheimer's disease and related disorders2007 · Nat Rev Neurosci · PMID 17612498Open reference}8^{2Tau-mediated neurodegeneration in Alzheimer's disease and related disorders2007 · Nat Rev Neurosci · PMID 17612498Open reference}9^{3PNT001, a conformation-specific antibody against pathological tau2019 · Acta Neuropathol · PMID 31161340Open reference}0:

Approach	Example	Status
Passive immunization	PNT001, Semorinemab	Phase 1/2
Active immunization	ACI-35	Phase 1/2
Small molecule inhibitors	LMTX	Phase 3
Kinase inhibitors	Tideglusib	Phase 2

Differentiation

PNT001 differentiates from other anti-tau antibodies through:

1. Higher specificity for pathological tau conformations

2. Oligomer targeting rather than total tau

3. PHF specificity - direct binding to NFTs

4. Clinical proof-of-concept from Phase 1

Research Directions

Biomarker Development

• Tau oligomer assays in CSF/plasma

• Tau PET with new tracers

• Synaptic markers (neurogranin, SNAP-25)

• Neurodegeneration markers (NfL)

Combination Strategies

• With anti-amyloid antibodies (lecanemab, donanemab)

• With disease-modifying small molecules

• With symptomatic treatments

Earlier Intervention

• Preclinical AD with biomarker positivity

• Genetic risk carriers (MAPT mutations)

• Prodromal tauopathies

• Allen Human Brain Atlas